Insulin Receptor
Insulin receptor (IR), a phylogenetically ancient tyrosine kinase receptor, is a large cell surface glycoprotein that concentrates insulin at the site of action and also initiates responses to insulin. The receptor is a disulfide-linked oligomer comprised of two alpha and two beta subunits. The insulin receptor exists in two isoforms, IR-A and IR-B, expressed in different relative abundance in the various organs and tissues. The two IR isoforms have similar binding affinity for insulin but different affinity for insulin-like growth factor (IGF)-2 and proinsulin, which are bound by IR-A but not IR-B.
The insulin receptor has a crucial role in controlling glucose homeostasis, regulating lipid, protein and carbohydrate metabolism, and modulating brain neurotransmitter levels. Insulin receptor dysfunction has been associated with many diseases, including diabetes, cancer and Alzheimer's disease.
All Product Categories
-
Insulin Receptor Inhibitors
(62)
View all products
-
Insulin Receptor Agonists
(34)
View all products
-
Insulin Receptor Antagonists
(12)
View all products
-
Insulin Receptor Activators
(35)
View all products
-
Insulin Receptor Modulators
(5)
View all products
-
Insulin Receptor Inducer
(1)
View all products
-
Insulin Receptor Degrader
(1)
View all products
-
Insulin Receptor Substrates
(3)
View all products
-
Insulin Receptor Ligand
(1)
View all products
-
Insulin Receptor (INSR) Proteins
(5)
View all products
-
INSR/CD220 Proteins
(7)
View all products
-
Insulin Receptor Related Products (205)
Related Products (205)
-
Recombinant Proteins (8)
-
Antibodies (8)
-
D-Galactose pentaacetate
0 ImagesCat. No.: HY-W102387CAS No.: 25878-60-8Synonyms: Pentaacetyl-D-galactopyranoseD-Galactose pentaacetate inhibits leucine-induced insulin release. D-Galactose pentaacetate can be used for the research of persistent hyperinsulinemia in childhood or insulinoma.
-
Rhoifolin (Standard)
0 ImagesRhoifolin (Standard) is the analytical standard of Rhoifolin. This product is intended for research and analytical applications. Rhoifolin is a flavone glycoside can be isolated from Rhus succedanea. Rhoifolin has anti-diabetic effect acting through enhanced adiponectin secretion, tyrosine phosphorylation of insulin receptor-β and glucose transporter 4 (GLUT 4) translocation. Rhoifolin has an anti-inflammatory action via multi-level regulation of inflammatory mediators. Rhoifolin ameliorates titanium particle-stimulated osteolysis and attenuates osteoclastogenesis via RANKL-induced NF-κB and MAPK pathways. Rhoifolin also has cytotoxic activity against different cancer cell lines.
-
NBI-6024
0 ImagesCat. No.: HY-106171CAS No.: 239480-61-6NBI-6024, an altered peptide ligand (APL), is an epitope recognized by inflammatory interferon-gamma-producing T helper lymphocytes in type 1 diabetic patients.
-
GIP, rat
0 ImagesCat. No.: HY-P5390Purity: 98.44%GIP, rat is a bioactive peptide derived from rats. GIP, rat inhibits GIP-mediated postprandial insulin release as well as GIP-promoted glucose uptake in the upper small intestine. GIP, rat can be used in research related to insulin resistance, glucose intolerance, and type 2 diabetes.
-
HNMPA
0 ImagesHNMPA is a membrane impermeable insulin receptor tyrosine kinase inhibitor. HNMPA inhibits serine and tyrosine autophosphorylation by the human insulin receptor. HNMPA has no effect on protein kinase C or cyclic AMP-dependent protein kinase activities
-
Pancreastatin (37-52), human
0 ImagesCat. No.: HY-P3864CAS No.: 133605-57-9Pancreastatin (37-52), human is a pancreastatin fragment. Pancreastatin a CgA-derived peptide (CgA residues 250–301) with biological activity, inhibited the releasing of insulin by islet beta cells.
-
Bilpatide
0 ImagesCat. No.: HY-P12137CAS No.: 2869056-74-4Synonyms: RAY1225Bilpatide (RAY1225) is a dual agonist of glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR). Bilpatide is applicable to research related to obesity and diabetes.
-
SaRI 59-801
0 ImagesCat. No.: HY-121565CAS No.: 80565-58-8
-
IMP2-IN-3
0 ImagesCat. No.: HY-150255CAS No.: 1448353-63-6IMP2-IN-3 is a potent IMP2 inhibitor. IMP2-IN-3 shows anticancer effects.
-
Xenin-8 acetate
0 ImagesCat. No.: HY-P1257BXenin-8 acetate is the C-terminal octapeptide fragment of xenin, which belongs to the xenopsin family of peptides. Xenin-8 acetate stimulates basal insulin secretion, dose-dependently enhances glucose (EC50 = 0.16 nM) and arginine-induced insulin release, and enhances arginine- and Carbamoylcholine chloride (HY-B1208)-induced glucagon secretion. Xenin-8 acetate antagonizes the inhibition of glucagon release by elevated glucose. Xenin-8 acetate can be used in research on type 2 diabetes and obesity-related glucose metabolic disorders.
-
Ceritinib mesylate
0 ImagesCat. No.: HY-15656BCAS No.: 2055376-74-2Synonyms: LDK378 mesylate
-
Glyceollin III
0 ImagesCat. No.: HY-N18033CAS No.: 61080-23-7Glyceollin III is a glyceollin found in soybeans. Glyceollin III enhances insulin-stimulated glucose uptake and increases glucagon-like peptide-1 (GLP-1) secretion. Glyceollin III can be used for the research of type 2 diabetes.
![[Pro3]-GIP (Rat)](https://file.medchemexpress.com/product_pic/hy-p1433.gif "Click to View [Pro3]-GIP (Rat) Product Detail")
-
Tirzepatide sodium
0 ImagesCat. No.: HY-P1731CPurity: 99.88%Synonyms: LY3298176 sodiumTirzepatide sodium (LY3298176 sodium) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide sodium exerts anti-apoptotic and pro-differentiation effects via the pAkt/CREB/BDNF cascade and miRNA in neurons; in the heart, it promotes BCAA catabolism and inhibits the mTOR pathway by mediating the dephosphorylation of BCKDHA; meanwhile, it effectively reduces insulin and leptin levels and suppresses inflammatory responses at the systemic level. Tirzepatide sodium can be used for research on myocardial infarction, colon cancer, diabetes, diabetic cognitive impairment, neurodegeneration, diabetes-related neuropathy, and obesity.
-
BMS-986118
0 ImagesCat. No.: HY-12413ACAS No.: 1610562-74-7BMS-986118 is an orally active and selective GPR40 full agonist (EC50 = 0.07 μM). BMS-986118 induces GLP-1 secretion and increases GLP-1 and insulin levels when combined with DPP-4 inhibitors. BMS-986118 shows sustained glucose-lowering effects. BMS-986118 can be used for research on type 2 diabetes.
-
[Tyr0] Gastric Inhibitory Peptide (23-42), human
![[Tyr0] Gastric Inhibitory Peptide (23-42), human](https://file.medchemexpress.com/product_pic/hy-p3577.gif "Click to View [Tyr0] Gastric Inhibitory Peptide (23-42), human Product Detail")
0 ImagesCat. No.: HY-P3577CAS No.: 121765-67-1[Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak inhibitor of gastric acid secretion that also stimulates insulin secretion. [Tyr0] Gastric Inhibitory Peptide (23-42), human can be used in diabetes, obesity research.
-
IRS-1 Peptide, FAM labeled
0 ImagesCat. No.: HY-P5433FCAS No.: 1600503-54-5IRS-1 Peptide, FAM labeled is a biological active peptide. (Insulin receptor substrate)
-
GTx-134
0 ImagesCat. No.: HY-13312ACAS No.: 1008448-19-8GTx-134 is a dual insulin-like growth factor 1 receptor/insulin receptor (IGF-1R/IR) inhibitor with an IC50 values for IGF-1R and IR of 97 and 187 nM respectively. GTx-134 inhibits the autophosphorylation of IGF-1R and its downstream signaling pathway (Akt), thereby blocking the proliferation and survival signals of tumor cells. GTx-134 has broad-spectrum inhibitory activity against multiple myeloma cell lines and can induce apoptosis in sensitive cells. GTx-134 significantly inhibits tumor growth in mice with MM1.S cell transplantation. GTx-134 works in synergy with existing therapies (such as protease preparations, immunomodulators). GTx-134 can be used in high-risk myeloma research.
-
CPF-7
0 ImagesCat. No.: HY-P5291CAS No.: 103238-06-8Synonyms: Caerulein precursor fragmentCPF-7 (Caerulein precursor fragment) is an insulin-releasing peptide that stimulates the release of insulin. CPF-7 can induce epithelial-mesenchymal transition by upregulating Snai1 expression in PANC-1 ductal cells. CPF-7 also induces exocrine plasticity by upregulating Ngn3 expression. CPF-7 can be used in the research of type 2 diabetes.
-
BM-131246
0 ImagesCat. No.: HY-101758CAS No.: 103787-97-9BM-131246 is an oral antidiabetic agent.
